Market Overview

UPDATE: Morgan Stanley Downgrades Teva Pharmaceutical on Earnings Pressure

Share:
Related TEVA
Report Sees 'Cognitive Dissonance' In Mylan's Internal Price Target
Analyst: Mylan Shareholders Might Get Convinced By Vigodman Letter
Teva Pharmaceutical Is Overvalued - Cramer's Lightning Round (5/5/15) (Seeking Alpha)

In a report published Monday, Morgan Stanley analyst David Risinger downgraded Teva Pharmaceutical (NYSE: TEVA) from Equal-Weight to Underweight, and removed the $40.00 price target.

In the report, Morgan Stanley noted, “Earnings face significant pressure in 2014-2017E when Copaxone, Treanda, and Nuvigil go generic. Copaxone margin pressure offsets cost cuts in our base case. Despite discounted valuation, we believe other stocks in our coverage universe offer a better risk-reward on revenue and growth prospects. Bull/bear cases continue to hinge on Copaxone franchise durability. Brand pipeline success, cost cutting, and external deals could drive upside.”

Teva Pharmaceutical closed on Friday at $38.91.

Latest Ratings for TEVA

DateFirmActionFromTo
Apr 2015Standpoint ResearchUpgradesHoldBuy
Apr 2015Argus ResearchMaintainsBuy
Apr 2015BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Downgrades Analyst Ratings

 

Related Articles (TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters